Item 8.01 Other Events.

On January 8, 2020, Blueprint Medicines Corporation (the "Company") issued a press release announcing top-line data from its Phase 1/2 ARROW clinical trial evaluating pralsetinib for the treatment of patients with RET fusion-positive non-small cell lung cancer ("NSCLC") and that the Company has initiated the submission of a rolling new drug application ("NDA") to the U.S. Food and Drug Administration for the treatment of patients with RET fusion-positive NSCLC. The Company expects to complete the NDA submission in the first quarter of 2020. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.


Exhibit No.    Description
99.1             Press release issued by Blueprint Medicines Corporation on
               January 8, 2020
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)




                                       2

© Edgar Online, source Glimpses